Copy to clipboard 
Integra reported 2Q20 orthopedic revenue of USD $11.2 million, -48.7% vs. 2Q19. The company endured -80% orthopedic revenue reductions in April. The quarter brought sequential improvements, with orthopedics recovering to mid-single-digit declines in June. Integra’s shoulder products showed the most growth and benefited from previously deferred procedures. The company expects 3Q revenue declines between -5% and -15% compared to the prior year, while 4Q revenues could approach 2019 levels.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 2Q20 | 2Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement Extremities | $4.1 | $9.1 | ($5.0) | (54.8%) |
| Trauma | $7.0 | $12.6 | ($5.6) | (44.3%) |
| Total | $11.2 | $21.8 | ($10.6) | (48.7%) |
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement Extremities | $12.5 | $18.2 | ($5.7) | (31.3%) |
| Trauma | $20.1 | $26.2 | ($6.1) | (23.3%) |
| Total | $32.6 | $44.4 | ($11.8) | (26.6%) |
Geographic Sales
| 2Q20 | 2Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $7.8 | $15.5 | ($7.7) | (49.4%) |
| OUS | $3.3 | $6.3 | ($2.9) | (47%) |
| EMEA | $1.4 | $2.9 | ($1.5) | (52.1%) |
| Asia Pacific | $1.4 | $2.1 | ($0.7) | (31.2%) |
| Rest of World | $0.5 | $1.3 | ($0.8) | (61.6%) |
| Total | $11.2 | $21.8 | ($10.6) | (48.7%) |
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $22.8 | $31.7 | ($8.9) | (28.1%) |
| OUS | $9.8 | $12.7 | ($2.9) | (22.9%) |
| EMEA | $4.2 | $6.0 | ($1.8) | (30.1%) |
| Asia Pacific | $3.9 | $4.4 | ($0.5) | (11.1%) |
| Rest of World | $1.8 | $2.4 | ($0.6) | (26.4%) |
| Total | $32.6 | $44.4 | ($11.8) | (26.6%) |
Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $258.7 | |
| Cost of Sales | $105.5 | 40.8% |
| Selling and Admin | $116.1 | 44.9% |
| R & D | $14.9 | 5.8% |
| Other | $22.5 | 8.7% |
| Net Earnings | ($0.4) | 0.1% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Integra reported 2Q20 orthopedic revenue of USD $11.2 million, -48.7% vs. 2Q19. The company endured -80% orthopedic revenue reductions in April. The quarter brought sequential improvements, with orthopedics recovering to mid-single-digit declines in June. Integra's shoulder products showed the most growth and benefited from previously...
Integra reported 2Q20 orthopedic revenue of USD $11.2 million, -48.7% vs. 2Q19. The company endured -80% orthopedic revenue reductions in April. The quarter brought sequential improvements, with orthopedics recovering to mid-single-digit declines in June. Integra’s shoulder products showed the most growth and benefited from previously deferred procedures. The company expects 3Q revenue declines between -5% and -15% compared to the prior year, while 4Q revenues could approach 2019 levels.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 2Q20 | 2Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement Extremities | $4.1 | $9.1 | ($5.0) | (54.8%) |
| Trauma | $7.0 | $12.6 | ($5.6) | (44.3%) |
| Total | $11.2 | $21.8 | ($10.6) | (48.7%) |
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement Extremities | $12.5 | $18.2 | ($5.7) | (31.3%) |
| Trauma | $20.1 | $26.2 | ($6.1) | (23.3%) |
| Total | $32.6 | $44.4 | ($11.8) | (26.6%) |
Geographic Sales
| 2Q20 | 2Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $7.8 | $15.5 | ($7.7) | (49.4%) |
| OUS | $3.3 | $6.3 | ($2.9) | (47%) |
| EMEA | $1.4 | $2.9 | ($1.5) | (52.1%) |
| Asia Pacific | $1.4 | $2.1 | ($0.7) | (31.2%) |
| Rest of World | $0.5 | $1.3 | ($0.8) | (61.6%) |
| Total | $11.2 | $21.8 | ($10.6) | (48.7%) |
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $22.8 | $31.7 | ($8.9) | (28.1%) |
| OUS | $9.8 | $12.7 | ($2.9) | (22.9%) |
| EMEA | $4.2 | $6.0 | ($1.8) | (30.1%) |
| Asia Pacific | $3.9 | $4.4 | ($0.5) | (11.1%) |
| Rest of World | $1.8 | $2.4 | ($0.6) | (26.4%) |
| Total | $32.6 | $44.4 | ($11.8) | (26.6%) |
Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $258.7 | |
| Cost of Sales | $105.5 | 40.8% |
| Selling and Admin | $116.1 | 44.9% |
| R & D | $14.9 | 5.8% |
| Other | $22.5 | 8.7% |
| Net Earnings | ($0.4) | 0.1% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
